Loading
A phase 3 trial of mebendazole in colorectal cancer, run by Sherief Abd-Elsalam, now recruiting.
Mebendazole as Adjuvant Treatment for Colon Cancer is a phase 3, randomised interventional study registered as NCT03925662 by Sherief Abd-Elsalam, with a registry enrolment figure of 40 participants, started 2019-04-01 and due to reach its primary completion in 2028-12. Interventions recorded: Folfox with avastin; Mebendazole. Conditions listed: Colorectal Cancer. Primary outcome: number of patients with tumour response. Colorectal eligibility wording from the registry: "* Colorectal cancer stage 4". Sites: Egypt. No results are recorded here; the registry entry is the source.
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.